DexCom (NASDAQ:DXCM) Rating Lowered to Underweight at Barclays

DexCom (NASDAQ:DXCM) was downgraded by investment analysts at Barclays from an “equal weight” rating to an “underweight” rating in a research report issued on Monday. They presently have a $71.00 target price on the medical device company’s stock. Barclays‘s price target points to a potential upside of 5.34% from the company’s current price.

Other research analysts have also recently issued research reports about the stock. Royal Bank Of Canada dropped their target price on shares of DexCom from $100.00 to $85.00 and set an “outperform” rating for the company in a report on Friday, October 31st. Wall Street Zen downgraded DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 16th. Mizuho increased their target price on shares of DexCom from $75.00 to $78.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Wells Fargo & Company set a $93.00 price objective on DexCom and gave the company an “overweight” rating in a report on Friday, October 31st. Finally, JPMorgan Chase & Co. dropped their price target on shares of DexCom from $90.00 to $75.00 and set a “neutral” rating on the stock in a research report on Friday, October 31st. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $86.30.

DexCom Stock Performance

Shares of DexCom stock opened at $67.40 on Monday. The firm has a market cap of $26.29 billion, a price-to-earnings ratio of 37.44, a price-to-earnings-growth ratio of 1.21 and a beta of 1.48. DexCom has a one year low of $54.11 and a one year high of $93.25. The stock’s 50-day moving average is $63.92 and its 200-day moving average is $72.00. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.56 and a quick ratio of 1.38.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The firm had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.18 billion. During the same quarter in the previous year, the business earned $0.45 earnings per share. The business’s revenue was up 21.6% compared to the same quarter last year. Equities analysts predict that DexCom will post 2.03 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In other DexCom news, COO Jacob Steven Leach bought 18,200 shares of DexCom stock in a transaction on Monday, November 10th. The stock was acquired at an average cost of $55.04 per share, with a total value of $1,001,728.00. Following the completion of the acquisition, the chief operating officer owned 331,697 shares in the company, valued at approximately $18,256,602.88. This represents a 5.81% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Richard Alexander Collins sold 2,906 shares of DexCom stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $59.05, for a total value of $171,599.30. Following the transaction, the director directly owned 35,088 shares in the company, valued at approximately $2,071,946.40. The trade was a 7.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 7,866 shares of company stock worth $448,177. 0.32% of the stock is currently owned by insiders.

Institutional Trading of DexCom

A number of institutional investors have recently bought and sold shares of the stock. Capital Asset Advisory Services LLC acquired a new position in shares of DexCom during the 4th quarter worth approximately $204,000. Clear Trail Advisors LLC purchased a new position in DexCom during the fourth quarter worth about $249,000. Assenagon Asset Management S.A. increased its holdings in DexCom by 48.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,226,449 shares of the medical device company’s stock valued at $81,399,000 after purchasing an additional 397,690 shares during the last quarter. Diversified Trust Co. lifted its stake in DexCom by 17.6% during the 4th quarter. Diversified Trust Co. now owns 11,524 shares of the medical device company’s stock worth $765,000 after acquiring an additional 1,726 shares in the last quarter. Finally, True Wealth Design LLC boosted its stake in shares of DexCom by 936.5% in the fourth quarter. True Wealth Design LLC now owns 995 shares of the medical device company’s stock valued at $66,000 after purchasing an additional 899 shares during the period. 97.75% of the stock is currently owned by institutional investors.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.